id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-297652-ut6e1ysz	Vanden Eynde, Jean Jacques	COVID-19: A Brief Overview of the Discovery Clinical Trial	2020-04-10		.txt	text/plain	3140	191	58	The study is entitled "Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)" (NCT04315948) [4] . In a MERS-CoV mouse model, the combination lopinavir/ritonavir/interferon β-1a, used as prophylactic and curative treatments, revealed no significant decrease in the viral load [9] . The results of an ongoing clinical trial (NCT Pharmaceuticals 2020, 13, 65 5 of 8 02845843 [4]), entitled "MERS-CoV infection treated with a combination of lopinavir/ritonavir and interferon Beta-1b", are eagerly awaited, but will not be disclosed before 2021. On March 28, the FDA issued an Emergency Use Authorization for use of hydroxychloroquine and chloroquine for patients who do not have access to the drugs via clinical trials [36] . The first cases of COVID-19 emerged in Wuhan, China, in late 2019, and to date there is no approved specific drug to cure patients infected by SARS-CoV-2. In Vitro Antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	./cache/cord-297652-ut6e1ysz.txt	./txt/cord-297652-ut6e1ysz.txt